References
- Pavenski K, Licht C, Kirchfink M. Utility of complement and ADAMTS13 testing in diagnosis of thrombotic microangiopathy: a single centre retrospective review. Hematology. 2014;124:2787.
- Mannucci PM, Peyvandi F. TTP and ADAMTS13: when is testing appropriate? Hematol Am Soc Hematol Educ Program. 2007;121–126. doi:10.1182/asheducation-2007.1.121.
- Kremer Hovinga JA, Lämmle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Program. 2012;2012:610–616. doi:10.1182/asheducation-2012.1.610.
- Schiviz A, Wuersch K, Piskernik C, et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood. 2012;119:6128–6135. doi:10.1182/blood-2011-09-380535.
- Tersteeg C, Schiviz A, De Meyer SF, et al. Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol. 2015;35:2336–2342. doi:10.1161/ATVBAHA.115.306014.
- Feys HB, Roodt J, Vandeputte N, et al. Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. Blood. 2012;120:3611–3614. doi:10.1182/blood-2012-04-421248.
- Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012;120:3603–3610. doi:10.1182/blood-2012-04-420943.
- Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374:511–522. doi:10.1056/NEJMoa1505533.
- Verbeke L, Delforge M, Dierickx D. Current insight into thrombotic thrombocytopenic purpura. Blood Coagul Fibrin. 2010;21:3–10. doi:10.1097/MBC.0b013e32833335eb.
- Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500–1511; quiz 662. doi:10.1182/blood-2009-09-243790.
- Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med. 2014;5:15–23. doi:10.2147/JBM.S46458.
- Deford CC, Reese JA, Schwartz LH, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013;122:2023–2029; quiz 142. doi:10.1182/blood-2013-04-496752.
- Scully M, Thomas M, Underwood M, et al., collaborators of the UKTTPR. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124:211–219. doi:10.1182/blood-2014-02-553131.